TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16838647
Drug: Interferon therapy
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon therapy during induction therapy
Study: 16838647
Drug: Interferon as
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon as maintenance therapy for patients responding to first-line therapy
Study: 14738559
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy with 6 MU IFN alpha three times a week
Study: 7900949
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day zidovudine
Study: 25268567
Drug: High-dose progesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose progesterone (PG)
Study: 18584369
Drug: Hydroxocobalamin (2.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxocobalamin (2.5, 5, 7.5, or 10 g) administered intravenously over 7.5 to 30 minutes
Study: 11840792
Drug: Intracameral anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracameral anesthesia with 0.15 ml lidocaine 1%
Study: 10512276
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg phenytoin
Study: 6825391
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Bufferin
Study: 6825391
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg Bi-prin
Study: 6825391
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg Ecotrin
Study: 6825391
Drug: 650 mg
Normalized name: bran 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 650 mg S.R.A.
Study: 24994919
Drug: Room air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room air administered via nasal cannula
Study: 22822043
Drug: Crystalloid solution
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crystalloid solution (15 ml kg(‐1) over 30 min)
Study: 20354559
Drug: Multiple-micronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-micronutrient supplementation (micronutrient powder, syrup, and milk-based fortified-food supplement)
Study: 20354559
Drug: Fortified-food supplement
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fortified-food supplement (FFS)
Study: 15963096
Drug: Fluconazole (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (200 mg once daily for 4 days)
Study: 15963096
Drug: Control (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (150 microg oral dose of desogestrel alone)
Study: 10321421
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro Mix50 (50% insulin lispro/50% NPL)
Study: 10321421
Drug: Insulin lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin lispro mixtures
Study: 1872515
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate as sustained-release tablets of 22 mg Zn++ (Zinklet), administered three times daily for 8 weeks
Study: 19548438
Drug: Nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine 10 mg three times per day
Study: 23788270
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with irinotecan or temozolomide after 4 chemotherapy cycles (16 weeks)
Study: 12161007
Drug: Oxytocin (OT)
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin (OT) administered intravenously at a dose of 2.5 IU
Study: 12161007
Drug: Vehicle administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vehicle administration (control)
Study: 9617509
Drug: Risperidone 6
Normalized name: risperidone 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone 6 mg daily
Study: 9617509
Drug: Lithium 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium 800 to 1200 mg daily
Study: 7018166
Drug: Prostaglandin E2-tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin E2-tablets (0.5-1.5 mg/hr)
Study: 7018166
Drug: Intravenous oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous oxytocin (7.5-45 mIU/min)
Study: 28120350
Drug: Rhealba® Oat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhealba® Oat Extract-based emollient applied once or twice daily during a 2-week treatment phase
Study: 24499078
Drug: PAD drugs
Normalized name: Medicated Pad
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAD drugs (cilostazol or sarpogrelate), Group B: n = 37
Study: 18394770
Drug: Mandibular implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mandibular implant overdentures (IODs)
Study: 17516958
Drug: Placebo daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily throughout pregnancy (n = 357)
Study: 17516958
Drug: Ferrous sulphate
Normalized name: Ferrous sulphate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous sulphate (150 g tablet, containing 50 mg of elemental iron) daily throughout pregnancy (n = 370)
Study: 20231324
Drug: Sertraline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (200 mg/day)
Study: 8011502
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g/day of concentrated n-3 fatty acids)
Study: 30600173
Drug: Self-administered acupressure
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Self-administered acupressure
Study: 19604587
Drug: Reperfusion therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfusion therapy (including fibrinolysis and primary PCI)
Study: 20196389
Drug: Early surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early surfactant administration (2 hours after the first dose)
Study: 20196389
Drug: Late surfactant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Late surfactant administration (6 hours after the first dose)
Study: 3120571
Drug: Lacto-ovovegetarian diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lacto-ovovegetarian diet (L)
Study: 30547749
Drug: Repellent (N,N‐diethyl‐benzamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repellent (N,N‐diethyl‐benzamide - 12% w/w, cream) distributed by Village Health Volunteers (VHVs) during the malaria transmission season.
Study: 20510211
Drug: High bolus
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High bolus dose tirofiban
Study: 12812864
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day methylprednisolone given IV for 5 days, then PO taper down
Study: 10754621
Drug: Undiluted propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undiluted propofol infusion at rates of 10, 15, 20, 30, 40, 60, 100, 200, and 300 mg/kg‐1/h‐1
Study: 10754621
Drug: Diluted propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Diluted propofol (0.5 mg/ml) infusion at rates of 10, 15, 30, 60, 100, 200, and 300 mg/kg‐1/h‐1
Study: 8796792
Drug: 0.25 mg/2
Normalized name: budesonide 0.25 mg/2 mL inhalation suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25 mg/2 ml PGE2 gel
Study: 8796792
Drug: 0.5 mg/2
Normalized name: femhrt 0.5 mg/2.5 mcg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/2 ml PGE2 gel
Study: 1639464
Drug: 1 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 ml/kg ethanol (vodka)
Study: 6539613
Drug: Intravenous application
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous application of cyclophosphamide (CP)
Study: 15765254
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate (EV) 2 mg alone
Study: 12081158
Drug: Dapsone 100
Normalized name: dapsone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapsone 100 mg daily
Study: 27900169
Drug: Non-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-treatment control group
Study: 830372
Drug: Etiocholanolone (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etiocholanolone (0.3 mg/kg)
Study: 30289355
Drug: alemtuzumab 12
Normalized name: alemtuzumab 12 MG in 1.2 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: alemtuzumab 12 mg
Study: 30289355
Drug: SC IFNB-1a
Normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SC IFNB-1a 44 μg
Study: 29059133
Drug: MK-0657 (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-0657 (7 mg)
Study: 25935606
Drug: Lateral Collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lateral Collagen Meniscus Implant (CMI)
Study: 19302077
Drug: Intracameral lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracameral lidocaine (0.5 cc of 1% unpreserved lidocaine)
Study: 17034604
Drug: Intravesical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical therapy based on in vitro cytotoxicity assay
Study: 20377577
Drug: Single drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single drug regimen
Study: 17034604
Drug: Double-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-drug regimen
Study: 17034604
Drug: BCG with
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG with cytotoxic drugs
Study: 9663175
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg rifampin once daily
Study: 9663175
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg SB 216469 twice a day
Study: 9663175
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg SB 216469 three times a day
Study: 7816765
Drug: Multiple Dose
Normalized name: Rebetron, multiple dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple Dose (MD) regimen
Study: 21976055
Drug: Dose-dense albumin-bound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense albumin-bound paclitaxel (ab-P)
Study: 18316163
Drug: Garcinia cambogia
Normalized name: Garcinia Cambogia Fruit
DrugBank: Garcinia gummi-gutta fruit (DB14365)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garcinia cambogia extract (1667.3 mg/day equivalent to 1000 mg HCA/day)
Study: 25528350
Drug: Sedation with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sedation with a daily wake-up trial
Study: 12438058
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of gadobenate dimeglumine
Study: 27981738
Drug: Atrasentan 1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 1.25 mg/d
Study: 22850358
Drug: Other antimalarial
Normalized name: Other antimalarials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other antimalarial drugs
Study: 1493085
Drug: AH 21-132
Normalized name: phenylephrine hydrochloride Chewable Tablet [Ah-Chew D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH 21-132 (20 mg, 40 mg) infused intravenously over 15 min
Study: 1493085
Drug: AH 21-132
Normalized name: phenylephrine hydrochloride Chewable Tablet [Ah-Chew D]
Approvals — FDA: no, EMA: no, PMDA: no
Description: AH 21-132 (intravenous and inhaled routes)
Study: 29797109
Drug: PG/timolol fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: PG/timolol fixed combination therapy (switched group)
Study: 29797109
Drug: Adding topical
Normalized name: Stahist AD
DrugBank: Chlorcyclizine (DB08936)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adding topical ripasudil therapy (added group)
Study: 14632722
Drug: Regular human
Normalized name: insulin regular human recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular human insulin (HR)
Study: 8547676
Drug: Busulfan (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg)
Study: 27774921
Drug: Steroid ear
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid ear drops
Study: 24335695
Drug: Dose-Intensive (DI)
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose-Intensive (DI) chemotherapy (Regimen B, n = 166)
Study: 24335695
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose chemotherapy (Regimen A, n = 162)
Study: 23393711
Drug: Intensive intermittent
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive intermittent physical therapy
Study: 20862944
Drug: Acupuncture-drug compound
Normalized name: BENZOIN COMPOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture-drug compound anesthesia (Group A)
Study: 2058190
Drug: Pediatric dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pediatric dosing algorithm
Study: 6683463
Drug: Amrinone, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amrinone, 100 mg orally every 8 hours for 1 month
Study: 6683463
Drug: Conventional CHF
Normalized name: CHF 4227
DrugBank: CHF 4227 (DB05882)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional CHF medications alone
Study: 26927209
Drug: Personalised 3-month
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Personalised 3-month course of Occupational Therapy (OT) delivered by qualified therapists.
Study: 21423036
Drug: Silicone Ahmed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silicone Ahmed glaucoma valve implant with intravitreal triamcinolone acetonide
Study: 8527264
Drug: Metoprolol (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (4 mg)
Study: 8527264
Drug: Sotalol (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (20 mg)
Study: 8527264
Drug: Milrinone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milrinone (1 mg)
Study: 2508009
Drug: Oral challenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral challenge food test (OCFT)
Study: 25083980
Drug: Pyridoxalated hemoglobin
Normalized name: Pyridoxalated hemoglobin polyoxyethylene
DrugBank: Hemoximer (DB17600)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridoxalated hemoglobin polyoxyethylene (20 mg Hb/kg/hr)
Study: 23412099
Drug: Docetaxel 30
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 30 mg/m² on days 1 and 8, every 3 weeks and cetuximab 400 mg/m² on day 1, then 250 mg/m² weekly
Study: 17098084
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day rimonabant
Study: 9521264
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of treatment for another 6 months followed by withdrawal (n = 83)
Study: 2807448
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration therapy (ORT) introduced by health workers
Study: 22814485
Drug: Oral rehydration
Normalized name: Oral rehydration salt formulations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rehydration therapy (ORT)
Study: 4578361
Drug: PAS plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAS plus isoniazid daily
Study: 4578361
Drug: Streptomycin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Streptomycin plus isoniazid twice a week for 1 year, then once a week
Study: 26610166
Drug: Oxycodone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxycodone treatment for 5 days
Study: 30609164
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 5 days
Study: 28268064
Drug: Dabrafenib 150
Normalized name: Dabrafenib
DrugBank: Dabrafenib (DB08912)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Dabrafenib 150 mg orally twice per day plus trametinib 2 mg orally once per day
Study: 16502766
Drug: Erythromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (250 mg) + Fexofenadine (60 mg)
Study: 16502766
Drug: Fexofenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fexofenadine (60 mg) alone
Study: 31345012
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg orally once daily until disease progression
Study: 22169619
Drug: Modified gay-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified gay-specific cognitive behavioral therapy combined with low-cost contingency management (GCBT+CM)
Study: 22169619
Drug: Original gay-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Original gay-specific cognitive behavioral therapy (GCBT)
Study: 22796581
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg) administered preoperatively and postoperatively
Study: 16949710
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of live attenuated hepatitis A vaccine
Study: 16949710
Drug: Booster dose
Normalized name: SARS-COV-2 (COVID-19) Vaccine, mRNA (Moderna) 50 MCG/0.5 ML Intramuscular Suspension [MODERNA COVID-19 VACCINE BOOSTER DOSE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Booster dose of live attenuated hepatitis A vaccine
Study: 25545400
Drug: Metformin XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin XL
Study: 20946173
Drug: GSNO gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSNO gel (100 µM)
Study: 23190780
Drug: PncOMPC vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PncOMPC vaccine
Study: 15921511
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Hepatitis B vaccine)
Study: 11799385
Drug: EpiPen Jr
Normalized name: EpiPen JR 2-Pak
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EpiPen Jr (0.15 mg)
Study: 7975870
Drug: Hydroxyethylrutosides (HR)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyethylrutosides (HR) at a dose of 1000 mg/day for at least 4 weeks
Study: 2195102
Drug: 0.125 mg
Normalized name: digoxin 0.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.125 mg of triazolam
Study: 20130094
Drug: High-dose DHA
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose DHA (1200 mg/d)
Study: 15167512
Drug: I treatment
Normalized name: IOBENGUANE I 123
Approvals — FDA: no, EMA: no, PMDA: no
Description: I treatment
Study: 12225613
Drug: Pentaglobin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentaglobin (5 ml/kg per day for 3 consecutive days)
Study: 12225613
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (standard sepsis therapy without immunoglobulin)
Study: 5338377
Drug: 1-3 injections
Normalized name: menthol 1.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-3 injections of 1 ml of aluminium-phosphate-adsorbed tetanus toxoid more than 6 weeks apart
Study: 5338377
Drug: 2 or
Normalized name: CP-2 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 or 3 injections of influenza-virus vaccine
Study: 21600165
Drug: Quadruple regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple regimen (PPI + bismuth + amoxicillin + furazolidone, 10 days) plus dental plaque removal treatment
Study: 21600165
Drug: Quadruple regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadruple regimen (PPI + bismuth + amoxicillin + furazolidone)
Study: 10506598
Drug: Paclitaxel 250
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 250 mg/m(2) with amifostine 910 mg/m(2)
Study: 8895273
Drug: Chloroprocaine with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroprocaine with fentanyl 3 micrograms/mL (60 micrograms)
Study: 1803834
Drug: Ranitidine (Glaxo's
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine (Glaxo's formulation)
Study: 26796660
Drug: Spray coagulation
Normalized name: anti-inhibitor coagulant complex Injection [Feiba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spray coagulation
Study: 25195134
Drug: Docetaxel (D)
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel (D) combinations (D + other drug combinations)
Study: 12477219
Drug: MAGhaler dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGhaler dry powder inhaler with salbutamol (200 microg) at high peak inhaled flow rate (60 l/min)
Study: 12477219
Drug: MAGhaler dry
Approvals — FDA: no, EMA: no, PMDA: no
Description: MAGhaler dry powder inhaler with salbutamol (200 microg) at low peak inhaled flow rate (30 l/min)
Study: 7881698
Drug: Dornase alfa
Normalized name: Dornase Alfa
DrugBank: Dornase alfa (DB00003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dornase alfa (rhDNase), administered daily for 24 weeks
Study: 2039814
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of nifedipine and atenolol
Study: 31939849
Drug: 0.3 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg methadone for cardiac surgery
Study: 31939849
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg hydromorphone for spinal surgery
Study: 31939849
Drug: 12 μg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 μg/kg fentanyl for cardiac surgery
Study: 26584456
Drug: Topical Diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Diclofenac (20 mg bis in die)
Study: 22445438
Drug: Ketoconazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole (400 mg, days 8-14)
Study: 22445438
Drug: Erythromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin (500 mg three times daily, days 8-14)
Study: 12763985
Drug: Oral ferrous
Normalized name: ferrous fumarate Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ferrous sulphate (80 mg/day of elemental iron daily; n=75)
Study: 1357070
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg oral, every 6 hours for 48 hours) + Placebo + GHRH (100 micrograms i.v.)